Older women who take a short break from hormone therapy do not experience fewer false positives on their screening mammograms than women who continue to take the drugs, though a suspension is associated with small changes in breast density.
Older women who take a short break from hormone therapy do not experience fewer false positives on their screening mammograms than women who continue to take the drugs, though a suspension is associated with small changes in breast density.
Until now, it has been recommended that women suspend their hormone therapy for longer than three months under the assumption the pause will help reduce false positives responsible for unnecessary recalls and diagnostic mammography.
But a study at the Group Health Center for Health Studies in Seattle, WA, found that recall rates were 11.3% among the women who did not suspend hormone therapy, 12.3% for those who suspended therapy for one month, and 9.8% for those who suspended therapy for two months (Ann Intern Med 2009;150:752-765). The differences were not statistically significant.
Although halting therapy did not significantly affect recall rates, breast density–a characteristic associated with higher recall rates–slightly decreased.
The study covered 1704 menopausal or post-menopausal women aged 45 to 80 on hormonal therapy. Volunteers were randomly assigned to receive screening mammography without ceasing hormone therapy, ceasing therapy one month before mammography, or ceasing therapy for the two months before mammography.
Women who suspended hormone therapy for one month experienced a 0.9% decrease in breast density. Women who suspended therapy for two months saw a 1.5% decrease while women who stayed on hormone therapy experienced no change.
Menopausal symptoms increased when therapy was suspended and many women were adamant about sticking with the drugs when they were contracted about participating in the trial. Two-thirds of 5861 potential volunteers were ruled out because they refused to suspend hormone therapy.
The resistance to dropping hormone therapy suggests women are either not likely to comply with the protocol, or wouldn't participate in the study even if it meant reducing false positive rates, said Diana S.M. Buist, principal investigator.
The study proves, however, there is no benefit from stopping hormones for one to two months before a mammogram to try to improve mammographic quality, she said. Women who stop hormones for longer than two months however, are likely to see improvements in mammography based on results from other trials.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.